Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 197

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 197
---
 in each case regarding any accounting practices of 
 Clearwater;                                                                                                                                                                                                                                           |

| • |     | Clearwater’s financial statements; |

| • |     | Clearwater’s disclosure controls and procedures; |

| • |     | Clearwater’s internal accounting controls and procedures; |

| • |     | the absence of specified undisclosed liabilities; |

| • |     | the inapplicability of anti-takeover statutes to the Merger Agreement, the Support Agreements, the Transactions 
 and the transactions contemplated thereby; and                                                                  |

125

| • |     | the absence of any actions by, or knowledge of any facts or circumstances by, Clearwater or its subsidiaries that                                                        
 could reasonably be expected to prevent the Corporate Mergers, taken together, from qualifying as a reorganization within the meaning of Section 368(a) of the Code; and |

| • |     | the ownership and tax classification of Acquirer and Merger Sub. |

Except as otherwise provided in the Merger Agreement, the representations and warranties contained in the Merger Agreement will not survive the Effective Time. Material Adverse Effect Some of the representations and warranties in the Merger Agreement made by Enfusion are qualified as to materiality or Enfusion Material Adverse Effect. For purposes of the Merger Agreement, “ Enfusion Material Adverse Effect” means any change, effect, event, occurrence, development, condition or fact (collectively, “ Effects”) that, individually or in the aggregate with all other Effects, that (i) would reasonably be expected materially impede, materially delay or prevent Enfusion’s ability to consummate the transactions contemplated by the Merger Agreement or (ii) has had, or would reasonably be expected to have, a material adverse effect on the business, financial condition, assets, liabilities or results of operations of Enfusion and its subsidiaries, taken as a whole; provided, however, that none of the following (alone or in combination) will constitute or be taken into account in determining whether a Enfusion Material Adverse Effect has occurred or would reasonably be expected to occur pursuant to the foregoing clause (ii):

| (A) | the negotiation, execution, announcement or performance of the Merger Agreement or the pendency or consummation                                                                                                                                           
 of the Transactions or the other transactions contemplated by the Merger Agreement (including, solely to the extent it relates to the foregoing, any loss of or adverse change in the relationship of Enfusion and its subsidiaries with their respective 
 employees, investors, contractors, lenders,